Naslov
Traumatic brain injury and pioglitazone: benefits and limitations of neuroprotective therapy

Autori
Dolenec, Petra ; Pilipović, Kristina ; Delač, Ljerka ; Slavić, Ante ; Župan, Željko ; Župan, Gordana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pharmaca / - , 2022, 118-118

Skup
10th Croatian Congress of Pharmacology with International Participation & 1st Croatian Congress of Clinical Pharmacology with International Participation

Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
traumatic brain injury, pioglitazone, neuroprotection

Sažetak
Traumatic brain injury (TBI) affects millions of people worldwide. Despite numerous preclinical and clinical research of pathophysiology and therapy of TBI, it remains the most significant cause of mortality and long-term disability, especially in previously healthy young people. One of the possible reasons why there is no effective neuroprotective agent proven to improve outcomes in TBI patients could be the complex and heterogenous pathobiology of TBI. That includes different cellular, molecular, biochemical and metabolic events that lead to progressive tissue damage and associated cell death. Because the primary injury is irreversible and cannot be pharmacologically affected, novel pharmacological options have been focused on the secondary injury. The recent pharmacological investigations are directed mainly toward multifunctional drugs that could affect different harmful pathomechanisms included in TBI. Here, our studies on the effects of the multifunctional compound, a peroxisome proliferator-activated receptor γ agonist, pioglitazone, on the different parameters of the rat brain damage will be presented. This work was supported by University of Rijeka, project uniri- biomed-18-204 to Ž.G. (from 2021 to D.P.).

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA